Category: Clinical Trials

Dabigatran: Bye.

Ref: Re: Concerns over data in key dabigatran trial. BMJ 2014. — @Jor_H_R Sinceramente, los que detallas en esa carta me parecen importantes pero no tanto como para retractarlos, a no ser que sepas más :-) — Enrique Gavilán (@enriquegavilan) December 28, 2015 — 0.2 y 2 son diferentes. La relación sangrado-eventos (especificamente accidentes cerebrovasculares)…

Study 329

Dr. David Healy writes for Mad in America: While making money from the publication of pharmaceutical company trials, and in the face of a complete failure by industry to adhere to basic scientific norms and make data available, BMJ and other journals — although BMJ in particular — have run a series of articles on supposed…

“Clinical Trials, Investigaciones: Free / Gratis”

El mundo nuevo d ensayos clinicos EU (Vraylar se estudio en Colombia tambn) http://t.co/f6XRroyCE4 @medicossinmarca pic.twitter.com/amdAZYhfDA — Data Based Medicine (@RxISK) October 7, 2015 … — http://heightsdoctors.blogspot.com.co/ http://heightsdoctorsclinic.com/https://clinicaltrials.gov/ct2/results?term=cariprazine&Search=Search — # Location PI & hospital affiliation Organization Funding in 2014 001 Flowood, MS 39232 Joseph Kwentus, M.D.Brentwood Behavioral Precise Research Centers $897,985.70$51,813.42 002 Houston,…

[ . . . ] In conclusion, evidence based methods, including the funnel plot, should be evidence based. If treatment decisions are made on the basis of misleading methodological tests, the costs to patients and society could be high. Decisions guided by the easy assurance of a symmetrical funnel plot may overlook serious bias. Equally, it may be misleading to discredit and abandon valid evidence simply because of an asymmetrical funnel plot. The prevention of publication bias is much more desirable than any diagnostic or corrective analysis.

Lau Joseph, Ioannidis John P A, Terrin Norma, SchmidChristopher H, Olkin Ingram. The case of the misleading funnel plot

Supertrialistas: ¿una nueva modalidad olímpica? – @nogracias_eu

“Marc Casañas y Jorge Ramírez son dos voces críticas necesarias; Marc, estudiante avezado de nutrición, además de ser un incesante generador de noticias en su twiter, ya ha colaborado con nosotros con una estupenda crónica de la Jornada “Pastillas las justas” y ha realizado varias traducciones (como esta de un texto del BMJ sobre la…

Phase 4 Interventional studies from Spain (completed before Jan 2011): How many unpublished?

Coauthored with Marc Casañas. Background: A few days ago we started to analyze data of public clinical trial registries with recruitment centers located in Spain. Analyzing hidden data of research is crucial to determine the influence of publication bias (cherry-picking), if the intended purpose is the correct scientific appraisal of the evidence about the effectiveness…

Basic and clinical pharmacology of the “uroselective” α blocker tamsulosin: a critical analysis. #evidencelive 2015 (poster)

References Ramirez Jorge. Severe hypotension associated with α blocker tamsulosin. BMJ 2013; 347 :f6492 http://dx.doi.org/10.1136/bmj.f6492 Re: Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology | The BMJ. http://www.bmj.com/content/347/bmj.f6320/rr/698284

%d bloggers like this: